Company intelligence / Profile preview

Airway Therapeutics

Atlanta, Georgia, United Statesairwaytherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Completed Phase 1b trial of zelpultide alfa (AT-100) with favorable safety profile in preterm neonates at risk for BPD. No dose-limiting toxicities were found and indications of efficacy were observed. Planning to launch a multinational Phase 3 trial in December 2024.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Biologics (recombinant human protein)
Industry: Biotech

Drug pipeline

1 asset

zelpultide alfa

Beyond the preview

Go deeper on Airway Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Airway Therapeutics.

Explore the full profile